Total Knee Arthroplasty
Conditions
Keywords
Human Erythropoietin, Ferric Derisomaltose Injection
Brief summary
This study is a randomized, placebo-controlled, multicenter research design to investigate the effectiveness and safety of a single-dose intravenous iron combined with HuEPO hematopoietic mobilization before surgery in patients undergoing unilateral total knee arthroplasty for the first time.
Detailed description
This study is a randomized, placebo-controlled, multicenter research design to investigate the effectiveness and safety of a single-dose intravenous iron combined with HuEPO hematopoietic mobilization before surgery in patients undergoing unilateral total knee arthroplasty for the first time. The study consists of a pilot trial and a formal trial. The pilot trial plans to enroll 20 subjects, with 10 subjects randomly assigned to the experimental group and 10 subjects to the control group. After the successful completion of the pilot trial, its safety and effectiveness, as determined by the investigators, hematologists, orthopedic surgeons, and statisticians, and the formal trial will be initiated. The relevant information and results will also be submitted to the ethics review committee. The formal trial plans to enroll 399 eligible subjects, with a random allocation ratio of 2:1 to the experimental group or the control group. To ensure the safety of the subjects, the last subject in the pilot trial will be followed up for 21 days after surgery. The safety and effectiveness of the pilot trial results will be discussed by the investigators, hematologists, orthopedic surgeons, and statisticians before initiating the formal trial. The timing of medication, sample size, and visit points in the formal trial may be adjusted appropriately based on the results of the pilot trial.
Interventions
DRUGFerric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)
Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
OTHERBasic Treatment
Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
Sponsors
West China Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18 and 75 years (inclusive) and no gender restriction at the time of signing the informed consent form (ICF). * Patients who meet the diagnostic criteria for osteoarthritis according to the American College of Rheumatology (ACR) and are undergoing primary total knee arthroplasty due to end-stage osteoarthritis. Flexion deformity \<30°, varus deformity \<30°, valgus deformity \<20°. * Baseline hemoglobin level: 100g/L \< Hb \< 130g/L. * No deep venous thrombosis observed on preoperative bilateral lower limb venous color Doppler ultrasound. * The subject understands and voluntarily signs the written informed consent form (ICF) and is capable of complying with the scheduled visits and related procedures as outlined in the protocol.
Exclusion criteria
* Known allergy to any excipients in the investigational drugs iron sucrose and erythropoietin or a history of multiple allergies. * Mean corpuscular volume (MCV) \> 100 fL. * Numeric Rating Scale (NRS) score ≥ 3. * Presence of iron overload (serum ferritin \> 800 ng/ml) or iron utilization disorders (such as hemochromatosis and iron deposition disorders). * Blood disorders other than iron-deficiency anemia. * Blood transfusion within the past 30 days. * Use of iron preparations or HuEPO for the treatment of anemia within the past 30 days. * History of deep vein thrombosis or pulmonary embolism. * Patients with hypophosphatemia due to various causes. * BMI \< 18.5 kg/m2 or body weight \< 50 kg. * History of recent myocardial infarction, angina pectoris, cerebral infarction, or epileptic seizures within the past 6 months. * Use of medications affecting coagulation and antiplatelet function within the past week. * Moderate liver impairment: Decompensated liver cirrhosis or hepatitis, ALT, AST \> 3 times the upper limit of normal (ULN). * Moderate renal impairment: Serum creatinine (Cr) \> 150 µmol/L. * HIV or syphilis patients. * Pregnant or lactating women. * Participants who have previously participated in other clinical trials, provided the previous investigational drug exposure did not exceed 5 half-lives. * Acute infection, rheumatoid arthritis, or significant joint inflammation. * Patients deemed unsuitable to participate in this clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hemoglobin concentration | postoperative 14±3 days | Hemoglobin concentration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Transfusion rate and amount | postoperative 14±3 days | Transfusion rate and amount |
| Assess changes in serum ferritin and transferrin saturation | postoperative 14±3 days and 28±5 days | Assess changes in serum ferritin and transferrin saturation |
| Quality of life indicators (SF-12) | postoperative 28±5 days and 90±12 days | Quality of life indicators (SF-12) |
| The rates of adverse events (AE) | postoperative 90±12 days | Assessed according to NCI-CTCAE v5.0 criteria |
| Total blood loss | postoperative 3±1 days | Total blood loss |
| The rates of laboratory abnormalities | postoperative 90±12 days | Assessed according to NCI-CTCAE v5.0 criteria |
| The rates of adverse events leading to drug discontinuation | postoperative 90±12 days | The rates of adverse events leading to drug discontinuation |
| The rates of adverse events leading to permanent discontinuation | postoperative 90±12 days | The rates of adverse events leading to permanent discontinuation |
| The rates of adverse events leading to early withdrawal from the study | postoperative 90±12 days | The rates of adverse events leading to early withdrawal from the study |
| The rates of serious adverse events (SAE) | postoperative 90±12 days | Assessed according to NCI-CTCAE v5.0 criteria |
Countries
China
Contacts
Primary ContactZeyu Huang, MD, PhD
Backup ContactFuxing Pei, MD, PhD
Outcome results
None listed